– UK, London – Avacta Group plc (LON: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of current Non-Executive Director Shaun Chilton as the Non-Executive Chairman with immediate effect, replacing Eliot Forster who is stepping down from the Board.
About Shaun Chilton
Shaun Chilton has served as a Non-Executive Director at Avacta since June 2023, having previously held the CEO position of Clinigen Group plc, a global pharmaceutical services group offering access to medicines, operating in over 100 countries. Shaun is an entrepreneurial biopharma executive and Chair with over 30 years of experience leading and managing both private and public businesses and a track record of delivering growth in sales and business enterprise value.
As CEO, he led the sale of Clinigen in 2022 to Triton Partners for a total consideration of c. £1.3 billion. Mr. Chilton has considerable board experience within UK public companies and has held several other board-level roles including serving as Non-Executive Chair of MAP Patient Access Ltd and C7 Health Ltd. As Chair of C7 Health Ltd, he led the sale of the business to a strategic buyer in 2022.
Shaun Chilton said: “I’ve worked in biopharma businesses for three decades and, having spent a year on the Board of Avacta, I understand the potential of the pre|CISION platform to transform the way we treat cancer. Avacta’s Board will continue to evolve to provide support for this platform and to ensure that we optimise the tremendous opportunity for patients and shareholders alike. I’m excited to be stepping into the role of Chair and to be working even more closely with the management team and wider Board.”
About Avacta Group plc
Avacta Group is a UK-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics.
Avacta Therapeutics: a clinical-stage oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs.
Avacta Diagnostics focuses on supporting healthcare professionals and broadening access to diagnostics.
Avacta has two proprietary platforms, pre|CISION and Affimer.
The pre|CISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION platform harnesses this tumor-specific protease to activate pre|CISION peptide drug conjugates and pre|CISION antibody/Affimer drug conjugates in the tumor microenvironment, reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.
The lead pre|CISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies. It has shown an improvement in safety and tolerability in clinical trials to date compared with standard doxorubicin and preliminary signs of clinical activity in multiple patients.
For more: https://www.avacta.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
